Experienced in Hairy Cell Leukemia (HCL)

Dr. Safi G. Shahda

Hematology Oncology
535 Barnhill Dr Rm 473, 
Indianapolis, IN 
Accepting New Patients
Experienced in Hairy Cell Leukemia (HCL)
535 Barnhill Dr Rm 473, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Safi Shahda is a Hematologist Oncology provider in Indianapolis, Indiana. Dr. Shahda is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Ampullary Cancer, and Pancreaticoduodenectomy. Dr. Shahda is currently accepting new patients.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hairy Cell Leukemia (HCL).

Specialties
Hematology Oncology
Licenses
Internal Medicine in IN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

535 Barnhill Dr Rm 473, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Panitumumab, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Enrollment Status: Unknown
Publish Date: February 06, 2023
Intervention Type: Drug, Device
Study Drug: Pembrolizumab
Study Phase: Early Phase 1
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Afatinib, Capecitabine
Study Phase: Phase 1
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection
A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug
Study Drug: FOLFIRINOX
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

39 Total Publications

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Journal: The New England journal of medicine
Published: September 26, 2025
Similar Doctors
Advanced in Hairy Cell Leukemia (HCL)
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine
Advanced in Hairy Cell Leukemia (HCL)
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine

Iu Health Medical Group LLC

1701 N Senate Ave, 
Indianapolis, IN 
 (0.5 miles away)
317-962-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Cripe is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Cripe is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Childhood Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Cripe is currently accepting new patients.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Sameer Z. Ahmed
Hematology Oncology | Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Sameer Z. Ahmed
Hematology Oncology | Hematology | Oncology

Franciscan Physician Network

1701 S Creasy Ln, 1w93, 
Lafayette, IN 
 (55.1 miles away)
765-502-4015
Languages Spoken:
English, Armenian, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sameer Ahmed is a Hematologist Oncology specialist and a Hematologist in Lafayette, Indiana. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Childhood Iron Deficiency Anemia, Lung Cancer, and Bone Marrow Aspiration. Dr. Ahmed is currently accepting new patients.

Experienced in Hairy Cell Leukemia (HCL)
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology
Experienced in Hairy Cell Leukemia (HCL)
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology

Indiana University Health Care Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (1.0 miles away)
317-944-4897
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Seyed Sayar is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Sayar is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Sayar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shahda's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile